We are live on
!
Find out more
RGLS
Regulus Therapeutics
RGLS
RGLS
Delisted
RGLS was delisted on the 24th of June, 2025.
25 hedge funds and large institutions have $15M invested in Regulus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
3.73% more ownership
Funds ownership: 52.23% → 55.97% (+3.7%)
0% more capital invested
Capital invested by funds: $15M → $15M (+$51.7K)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Holders
25
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
5
Closed
2
Calls
$535K
Puts
–
Net Calls
+$535K
Net Calls Change
-$45K
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.04M |
| 2 |
VF
Virtu Financial
New York
|
+$37.6K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$17K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.3K |
| 5 |
Renaissance Technologies
New York
|
+$5.8K |
Top Sellers
| 1 |
LPL Financial
San Diego,
California
|
-$27.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$23.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.15K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.64K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$580 |
